Investor Relations

Amicus Therapeutics (NASDAQ: FOLD) is pioneering a paradigm-shifting approach to treating a range of human genetic diseases in which crucial proteins are misfolded, thus reducing or eliminating their functionality. Amicus develops pharmacological chaperones - oral therapies that bind to and stabilize the affected proteins, restoring their shape, proper trafficking, and biological activity. This novel, next-generation approach offers the potential to improve treatment options for patients with genetic diseases.

Recent Releases

Jun 3, 2008
Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease

May 13, 2008
Amicus Therapeutics Announces First Quarter 2008 Financial Results

Events

May 13, 2008
Amicus Therapeutics First Quarter 2008 Results conference call

Apr 30, 2008
Morgan Stanley Global Healthcare Unplugged Conference